CN104940223A - 一种用于治疗心脏病的吸入式药物组合物及其制备方法 - Google Patents
一种用于治疗心脏病的吸入式药物组合物及其制备方法 Download PDFInfo
- Publication number
- CN104940223A CN104940223A CN201410337827.1A CN201410337827A CN104940223A CN 104940223 A CN104940223 A CN 104940223A CN 201410337827 A CN201410337827 A CN 201410337827A CN 104940223 A CN104940223 A CN 104940223A
- Authority
- CN
- China
- Prior art keywords
- inhaling
- medicinal compositions
- gas
- type medicinal
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 31
- 208000019622 heart disease Diseases 0.000 title abstract description 9
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 claims abstract description 142
- 239000007789 gas Substances 0.000 claims abstract description 92
- 239000001257 hydrogen Substances 0.000 claims abstract description 90
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 90
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 81
- 239000007788 liquid Substances 0.000 claims abstract description 66
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims abstract description 50
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 claims abstract description 25
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 claims abstract description 25
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 claims abstract description 25
- 229960002274 atenolol Drugs 0.000 claims abstract description 25
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 claims abstract description 25
- 229960004195 carvedilol Drugs 0.000 claims abstract description 25
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 claims abstract description 25
- 229960003009 clopidogrel Drugs 0.000 claims abstract description 25
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 claims abstract description 25
- 229960004166 diltiazem Drugs 0.000 claims abstract description 25
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 claims abstract description 25
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 claims abstract description 25
- 229960004255 nadolol Drugs 0.000 claims abstract description 25
- LBHIOVVIQHSOQN-UHFFFAOYSA-N nicorandil Chemical compound [O-][N+](=O)OCCNC(=O)C1=CC=CN=C1 LBHIOVVIQHSOQN-UHFFFAOYSA-N 0.000 claims abstract description 25
- 229960002497 nicorandil Drugs 0.000 claims abstract description 25
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims abstract description 25
- 229960001597 nifedipine Drugs 0.000 claims abstract description 25
- 229960003712 propranolol Drugs 0.000 claims abstract description 25
- 229960001722 verapamil Drugs 0.000 claims abstract description 25
- 229960000201 isosorbide dinitrate Drugs 0.000 claims abstract description 13
- 150000002431 hydrogen Chemical class 0.000 claims abstract description 9
- 230000003130 cardiopathic effect Effects 0.000 claims description 46
- 239000011800 void material Substances 0.000 claims description 43
- 238000000889 atomisation Methods 0.000 claims description 41
- 238000005868 electrolysis reaction Methods 0.000 claims description 35
- 239000001301 oxygen Substances 0.000 claims description 25
- 229910052760 oxygen Inorganic materials 0.000 claims description 25
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 24
- 239000012267 brine Substances 0.000 claims description 18
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 claims description 18
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 12
- PGHBYDVOOPRPQW-UHFFFAOYSA-N 1,3-dinitrooxypropan-2-yl nitrate Chemical group [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O.[O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O PGHBYDVOOPRPQW-UHFFFAOYSA-N 0.000 claims description 11
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 8
- 229910001882 dioxygen Inorganic materials 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 229910052756 noble gas Inorganic materials 0.000 claims description 5
- 239000003814 drug Substances 0.000 abstract description 23
- 230000000694 effects Effects 0.000 abstract description 9
- 150000003254 radicals Chemical class 0.000 abstract description 6
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 abstract description 5
- 239000000006 Nitroglycerin Substances 0.000 abstract description 4
- 238000010521 absorption reaction Methods 0.000 abstract description 4
- 229960003711 glyceryl trinitrate Drugs 0.000 abstract description 4
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 9
- 238000010586 diagram Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 7
- 208000029078 coronary artery disease Diseases 0.000 description 6
- 108091006146 Channels Proteins 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000000505 pernicious effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 208000015210 hypertensive heart disease Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 208000004124 rheumatic heart disease Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0085—Inhalators using ultrasonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/04—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised
- A61M11/041—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters
- A61M11/042—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters electrical
- A61M11/044—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters electrical with electrodes immersed in the liquid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/04—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised
- A61M11/041—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters
- A61M11/045—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters using another liquid as heat exchanger, e.g. bain-marie
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/36—General characteristics of the apparatus related to heating or cooling
- A61M2205/3693—General characteristics of the apparatus related to heating or cooling by mechanical waves, e.g. ultrasonic
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Otolaryngology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Oil, Petroleum & Natural Gas (AREA)
Abstract
本发明提供一种用于治疗心脏病的吸入式药物组合物及其制备方法,包含第一气体及雾化药液。第一气体包含氢气,氢气占吸入式药物组合物的气体体积浓度在2%~96%之间。雾化药液包含选自乙酰水杨酸、氯吡格雷、普萘洛尔、阿替洛尔、纳多洛尔、卡维地洛、硝苯吡啶、地尔硫卓、维拉帕米、硝酸异山梨酯、尼可地尔以及硝酸甘油所组成的组中之一或其组合。本发明吸入式药物组合物除了可以通过氢气去除患者体内的恶性自由基,并通过雾化药液以增加患者的药物吸收疗效,也因为使用少量雾化药液剂量,间接地降低药剂对人体产生的副作用。
Description
技术领域
本发明涉及一种吸入式药物组合物及其制备方法,特别涉及一种用于治疗心脏病的吸入式药物组合物及其制备方法。
背景技术
目前,随着人们生活水准的不断提高,生活状态改变及饮食习惯逐渐西化,以致心脏病(Heart Disease)患者人数大幅增加,且高居国内十大死因之一,同时发病年龄层也有明显下降的趋势,所以心脏病已经严重地威胁到人类健康。
心脏病是心脏疾病的总称,其影响着心脏的结构和功能,可分为先天性心脏病、风湿性心脏病、高血压性心脏病和冠状动脉心脏病,其中心脏病致病的主因是冠状动脉出现狭窄、硬化或阻塞以致心脏的血液供应不足而引起心脏缺氧,即所谓的冠状动脉心脏病(Coronary Artery Disease,CAD),其包含有冠状动脉硬化症、冠状动脉粥状硬化、冠心病、缺血性心脏病、心绞痛、狭心症、心肌梗塞。
其中于现有技术中,冠状动脉疾病的药物治疗法包括:抗血小板凝聚药物,如乙酰水杨酸(Acetylsalicylic Acid)、氯吡格雷(Clopidogrel);乙受型阻断剂,如普萘洛尔(Propranolol)、阿替洛尔(Atenolol)、纳多洛尔(Nadolol)、卡维地洛(Carvedilol);钙离子通道阻滞剂,如硝苯吡啶(Nifedipine)、地尔硫卓(Diltiazem)、维拉帕米(Verapamil);硝酸盐类,如硝酸异山梨酯(IsosorbideDinitrate)、尼可地尔(Nicorandil);以及硝酸甘油(Nitroglycerin,NTG)。然而,上述这些药物通常都存在有一些副作用,例如,服药后会出现如头痛或心跳加快等不良反应,甚至有患者在服用硝酸甘油后会出现昏迷的现象,使得这些药物不适合长期使用。
如上所述,因此目前缺乏一种能兼具治疗效果且降低对患者产生副作用的心脏病药剂。
发明内容
因此,本发明提供一种用于治疗心脏病的吸入式药物组合物,其包含第一气体及雾化药液。第一气体包含氢气,氢气占吸入式药物组合物的气体体积浓度在2%~96%之间。雾化药液包含选自乙酰水杨酸(Acetylsalicylic Acid)、氯吡格雷(Clopidogrel)、普萘洛尔(Propranolol)、阿替洛尔(Atenolol)、纳多洛尔(Nadolol)、卡维地洛(Carvedilol)、硝苯吡啶(Nifedipine)、地尔硫卓(Diltiazem)、维拉帕米(Verapamil)、硝酸异山梨酯(Isosorbide Dinitrate)、尼可地尔(Nicorandil)以及硝酸甘油(Nitroglycerin)所组成的组中之一或其组合。
根据本发明的一实施例提供一种用于治疗心脏病的吸入式药物组合物,第一气体是由电解水所产生的氢氧混合气体,其中氢气与氧气的体积比为2:1。于一实施例中,氢气占吸入式药物组合物的气体体积浓度在2%~66.66%之间。此外,本发明吸入式药物组合物还包含第二气体,用于降低吸入式药物组合物中氢气的气体体积浓度,其中第二气体为选自由空气、水蒸汽、惰性气体、氧气及其组合所组成的组中的一种气体。于另一实施例中,氢气占吸入式药物组合物的气体体积浓度在4.7%~66.66%之间。
根据本发明的另一实施例提供一种用于治疗心脏病的吸入式药物组合物,氢气占吸入式药物组合物的气体体积浓度在60%~66.66%之间。此外,于另一实施例提供一种用于治疗心脏病的吸入式药物组合物,氢气占吸入式药物组合物的气体体积浓度大于66.66%。
此外,本发明另提供一种用于治疗心脏病的吸入式药物组合物的制备方法,包含下列步骤:
(S1)制备第一气体,第一气体包含氢气;
(S2)雾化一药液以产生雾化药液,药液包含选自乙酰水杨酸(Acetylsalicylic Acid)、氯吡格雷(Clopidogrel)、普萘洛尔(Propranolol)、阿替洛尔(Atenolol)、纳多洛尔(Nadolol)、卡维地洛(Carvedilol)、硝苯吡啶(Nifedipine)、地尔硫卓(Diltiazem)、维拉帕米(Verapamil)、硝酸异山梨酯(Isosorbide Dinitrate)、尼可地尔(Nicorandil)以及硝酸甘油(Nitroglycerin)所组成的组中之一或其组合;以及
(S3)混合第一气体以及雾化药液以产生该吸入式药物组合物,其中氢气占吸入式药物组合物的气体体积浓度在2%~96%之间。
根据本发明的一实施例提供一种用于治疗心脏病的吸入式药物组合物的制备方法,本发明方法的步骤(S1)为电解水以产生第一气体,第一气体含氢氧混合气体,其中氢气与氧气的体积比为2:1。
根据本发明的另一实施例提供一种用于治疗心脏病的吸入式药物组合物的制备方法,本发明方法的步骤包含:
(S21)制备第一气体,第一气体包含氢气;
(S22)雾化一药液以产生雾化药液,药液包含选自乙酰水杨酸(Acetylsalicylic Acid)、氯吡格雷(Clopidogrel)、普萘洛尔(Propranolol)、阿替洛尔(Atenolol)、纳多洛尔(Nadolol)、卡维地洛(Carvedilol)、硝苯吡啶(Nifedipine)、地尔硫卓(Diltiazem)、维拉帕米(Verapamil)、硝酸异山梨酯(Isosorbide Dinitrate)、尼可地尔(Nicorandil)以及硝酸甘油(Nitroglycerin)所组成的组中之一或其组合;
(S23)准备第二气体;以及
(S24)混合第一气体、第二气体以及雾化药液以产生吸入式药物组合物,其中第二气体用于降低吸入式药物组合物中氢气的气体体积浓度。于此实施例中,本发明用于治疗心脏病的吸入式药物组合物中氢气占吸入式药物组合物的气体体积浓度,可因第二气体加入而降低吸入式药物组合物中氢气的气体体积浓度。
此外,根据本发明的另一实施例提供一种用于治疗心脏病的吸入式药物组合物的制备方法,其中氢气占吸入式药物组合物的气体体积浓度在60%~66.66%之间。于另一实施例提供一种用于治疗心脏病的吸入式药物组合物的制备方法,其中氢气占吸入式药物组合物的气体体积浓度大于66.66%。
相比于现有技术,本发明提供一种用于治疗心脏病的吸入式药物组合物及其制备方法,本发明吸入式药物组合物除了可以提供患者直接吸入的服用便利性外,并可以通过氢气以去除患者体内的恶性自由基,并通过雾化药液以增加患者的药物吸收疗效。
附图说明
图1是本发明用于治疗心脏病的吸入式药物组合物的制备方法于一具体实施例的方法流程图。
图2是本发明用于治疗心脏病的吸入式药物组合物的制备方法于另一具体实施例的方法流程图。
图3是本发明用于治疗心脏病的吸入式药物组合物的制备方法中步骤(S1)于一具体实施例的电解装置示意图。
图4是本发明用于治疗心脏病的吸入式药物组合物的制备方法中步骤(S2)及(S3)于一具体实施例的气体混合系统示意图。
具体实施方式
为了让本发明的优点,精神与特征可以更容易且明确地了解,后续将以实施例并参照所附附图进行详述与讨论。值得注意的是,这些实施例仅为本发明代表性的实施例,其中所举例的特定方法、装置、条件、材质等并非用以限定本发明或对应的实施例。
本发明提出一种用于治疗心脏病的吸入式药物组合物,包含第一气体及雾化药液。第一气体包含氢气,氢气占吸入式药物组合物的气体体积浓度在2%~96%之间。雾化药液包含选自乙酰水杨酸(Acetylsalicylic Acid)、氯吡格雷(Clopidogrel)、普萘洛尔(Propranolol)、阿替洛尔(Atenolol)、纳多洛尔(Nadolol)、卡维地洛(Carvedilol)、硝苯吡啶(Nifedipine)、地尔硫卓(Diltiazem)、维拉帕米(Verapamil)、硝酸异山梨酯(Isosorbide Dinitrate)、尼可地尔(Nicorandil)以及硝酸甘油(Nitroglycerin)所组成的组中之一或其组合。
于本发明的实施例中,第一气体还包含氧气,而第一气体是由电解水所产生的氢氧混合气体,其中氢气与氧气的体积比为2:1。而雾化药液则是由针对一药液进行雾化或挥发所产生,其中药液包含选自乙酰水杨酸(AcetylsalicylicAcid)、氯吡格雷(Clopidogrel)、普萘洛尔(Propranolol)、阿替洛尔(Atenolol)、纳多洛尔(Nadolol)、卡维地洛(Carvedilol)、硝苯吡啶(Nifedipine)、地尔硫卓(Diltiazem)、维拉帕米(Verapamil)、硝酸异山梨酯(Isosorbide Dinitrate)、尼可地尔(Nicorandil)以及硝酸甘油(Nitroglycerin)所组成的组中之一或其组合,且上述药物应用于心脏病治疗上已为本领域的技术人员所熟知,故在此不多加赘述。于本实施例中,氢气占吸入式药物组合物的气体体积浓度在2%~66.66%之间。
本发明吸入式药物组合物还包含第二气体,第二气体用于降低吸入式药物组合物中氢气的气体体积浓度,其中第二气体为选自由空气、水蒸汽、惰性气体、氧气及其组合所组成的组中的一种气体。于本实施例中,氢气占吸入式药物组合物的气体体积浓度可在4.7%~66.66%之间,惟不以此范围为限。
于另一具体实施例中,本发明吸入式药物组合物可以通过混合第一气体以及雾化一体积为40c.c.的药液所产生的雾化药液所制备,而氢气占吸入式药物组合物的气体体积浓度在60%~66.66%之间。于另一实施例中,也可以用氢气瓶提供所需氢气,并与雾化药液进行混合,此时氢气占吸入式药物组合物的气体体积浓度将可能会高于66.66%,例如67%~96%之间。于另一实施例中,也可直接收集电解水中所产生的氢气(而非氢氧混合气)直接与雾化药液进行混合,此时氢气占吸入式药物组合物的气体体积浓度将也会高于66.66%。
请参阅图1,图1是本发明用于治疗心脏病的吸入式药物组合物的制备方法于一具体实施例的方法流程图。如图所示,本发明吸入式药物组合物的制备方法包含下列步骤:
(S1)制备第一气体,第一气体包含有氢气;
(S2)雾化一药液以产生雾化药液,药液包含有选自乙酰水杨酸(Acetylsalicylic Acid)、氯吡格雷(Clopidogrel)、普萘洛尔(Propranolol)、阿替洛尔(Atenolol)、纳多洛尔(Nadolol)、卡维地洛(Carvedilol)、硝苯吡啶(Nifedipine)、地尔硫卓(Diltiazem)、维拉帕米(Verapamil)、硝酸异山梨酯(Isosorbide Dinitrate)、尼可地尔(Nicorandil)以及硝酸甘油(Nitroglycerin)所组成的组中之一或其组合;以及
(S3)混合第一气体以及雾化药液以产生吸入式药物组合物,其中氢气占吸入式药物组合物的气体体积浓度在2%~96%之间。
根据本发明的一实施例提供一种用于治疗心脏病的吸入式药物组合物的制备方法,本发明方法的步骤(S1)为电解水以产生第一气体,第一气体含氢氧混合气体,其中氢气与氧气的体积比为2:1。于一实施例中,氢气占吸入式药物组合物的气体体积浓度在2%~66.66%之间,惟不以此范围为限。
请参阅图2,图2是本发明用于治疗心脏病的吸入式药物组合物的制备方法于另一具体实施例的方法流程图。如图所示,本发明吸入式药物组合物的另一制备方法,包含下列步骤:
(S21)制备第一气体,第一气体包含有氢气;
(S22)雾化一药液以产生雾化药液,药液包含有选自乙酰水杨酸(Acetylsalicylic Acid)、氯吡格雷(Clopidogrel)、普萘洛尔(Propranolol)、阿替洛尔(Atenolol)、纳多洛尔(Nadolol)、卡维地洛(Carvedilol)、硝苯吡啶(Nifedipine)、地尔硫卓(Diltiazem)、维拉帕米(Verapamil)、硝酸异山梨酯(Isosorbide Dinitrate)、尼可地尔(Nicorandil)以及硝酸甘油(Nitroglycerin)所组成的组中之一或其组合;以及
(S23)准备第二气体;以及
(S24)混合第一气体、第二气体以及雾化药液以产生吸入式药物组合物。
根据本发明的一实施例提供一种用于治疗心脏病的吸入式药物组合物的制备方法,本发明方法的步骤(S21)为电解水以产生第一气体,第一气体含氢氧混合气体,其中氢气与氧气的体积比为2:1。此外,本发明用于治疗心脏病的吸入式药物组合物中氢气占吸入式药物组合物的气体体积浓度,可因第二气体加入而降低吸入式药物组合物中氢气的气体体积浓度,于本实施例中,氢气占吸入式药物组合物的气体体积浓度可在4.7%~66.66%之间,惟不以此范围为限。
当然,于另一实施例中,也可以用氢气瓶提供所需氢气,并与雾化药液进行混合,此时氢气占吸入式药物组合物的气体体积浓度将可能会高于66.66%,例如67%~96%之间。但因吸入气体中氢气体积浓度太高(如高于96%)可能使氧气体积浓度太低而对人体产生缺氧的不良影响,因此此时需注意控制氢气体积浓度不要高于96%,如在67%~90%之间。于另一实施例中,也可直接收集电解水中所产生的氢气(而非氢氧混合气)直接与雾化药液进行混合,此时氢气占吸入式药物组合物的气体体积浓度将也会高于66.66%。
请参阅图3,图3是本发明用于治疗心脏病的吸入式药物组合物的制备方法中步骤(S1)于一具体实施例的电解装置示意图。于本实施例中,本发明能够通过电解水以产生含有氢氧混合气体的第一气体,其中电解装置100包含电解槽102、电解水104、电极106A、106B以及电源。
首先,电解槽102用以容纳电解水104,其中电解水104主要成份为纯水,惟不以此为限,于实际应用时,电解水能够视需要以添加少量的电解质,如氢氧化钠、碳酸钙、氯化钠等。再者,电解槽102中包含电极106A、106B,电极106A、106B分别为一阴极电极及一阳极电极,并耦接至一电源(未绘示于图中),以提供电解水所需的电能。于一具体实施例中,电极106A、106B能够是固定的极性,如电极106A为阴极,电极106B为阳极,惟电极的极性不以固定为限。于另一具体实施例中,电极106A、106B能够是交替变换的极性,如在某一时间点,电极106A为阴极,电极106B为阳极;经过一预定时间后,在另一时间点,电极106A切换为阳极,电极106B切换为阴极,其后依此类推。
接着,电解槽102中的电解水104经过电极106A、106B通电后会开始电解,而在阴极(负极)产生氢气,阳极(正极)产生氧气,且释出于电解槽102的上部,以形成第一气体108,其中第一气体108由电解槽102的第一气体管路110输出,以作为后续的使用,惟不以此为限。于另一个实施例中,本发明亦能够将阴极产生的氢气与阳极产生的氧气,分别以一气体导管导引出电解槽102,之后再进行混合而产生第一气体108。
由于电解水104经过电解后所产生的氢气及氧气的体积比约为2:1。于一具体实施例中,本发明能够再添加第二气体112,以降低吸入式药物组合物中氢气的气体体积浓度,例如氢气占吸入式药物组合物的气体体积浓度可以控制在4.7%~66.66%之间,其中第二气体为选自由空气、水蒸汽、惰性气体、氧气及其组合所组成的组中的一种气体。
请参阅图4,图4是本发明用于治疗心脏病的吸入式药物组合物的制备方法中步骤(S2)及(S3)于一具体实施例的气体混合系统示意图。本发明吸入式药物组合物的制备方法中步骤(S2)及(S3)可以通过气体混合系统200,以雾化药液220并混合第一气体108进而产生吸入式药物组合物214。
气体混合系统200包含一雾化/挥发气体混合槽210,雾化/挥发气体混合槽210由第一气体管路110与电解装置100(如图3所示)耦接,以接收第一气体108,并与雾化药液212混合,以形成吸入式药物组合物214。雾化/挥发气体混合槽210还包括一震荡器216(例如超音波震荡器),适于对雾化/挥发气体混合槽210中药液220进行雾化,以产生雾化药液212。药液220可以为乙酰水杨酸(AcetylsalicylicAcid)、氯吡格雷(Clopidogrel)、普萘洛尔(Propranolol)、阿替洛尔(Atenolol)、纳多洛尔(Nadolol)、卡维地洛(Carvedilol)、硝苯吡啶(Nifedipine)、地尔硫卓(Diltiazem)、维拉帕米(Verapamil)、硝酸异山梨酯(Isosorbide Dinitrate)、尼可地尔(Nicorandil)以及硝酸甘油(Nitroglycerin)所组成的组中之一或其组合,且上述药物应用于心脏病治疗上已为本领域的技术人员所熟知,故在此不多加赘述。
于另一具体实施例中,雾化/挥发气体混合槽210中可容纳的药液约40~100c.c范围,预估以60分钟内雾化完毕,故雾化药液本身产气量约0.67cc/min~1.67cc/min之间,而电解槽102控制每分钟产气量约2,000cc/min~3,000cc/min之间,其中如电解槽产气结果仅仅是氢氧混合气(氢气及氧气的体积比约为2:1),则氢气占吸入式药物组合物的气体体积浓度在66.61%~66.65%之间。但有时因电解槽电解的热能,会蒸发电解水而使电解槽产气的结果除氢氧混合气外,还可能含有少量些许的水蒸气,因此氢气占吸入式药物组合物的气体体积浓度会低于66.61%,例如在60%~66.61%之间,当然上述的少量些许水蒸气可以通过降温而减少。本发明吸入式药物组合物的制备方法可以通过混合氢氧混合气以及雾化药液所制备,一般而言氢气占吸入式药物组合物的气体体积浓度在60%~66.66%之间。
于另一具体实施例中,第一气体及雾化药液在吸入式药物组合物中的组成含量比例依气体体积百分比浓度计得分别为35.33~99.99%及0.01~64.67%,但并不以此比例为限,于实际应用时,第一气体、雾化药液在吸入式药物组合物中的组成含量比例得视病人情况进行调整。于实际应用时,本发明之吸入式药物组合物得通过吸入并每天施用至少30~60分钟,每天为一次至三次。
此外,于另一具体实施例中,第一气体、雾化药液及第二气体在吸入式药物组合物中的组成含量比例依气体体积百分比浓度计得分别为33~97%、0.01~64%及2~66%,但并不以此比例为限,于实际应用时,第一气体、雾化药液及第二气体在吸入式药物组合物中的组成含量比例得视病人情况进行调整。于实际应用时,本发明的吸入式药物组合物得通过吸入并每天施用至少30~60分钟,每天为一次至三次。
由上述实施例可知,本发明吸入式药物组合物包含氢气与雾化药液,以提供患者(未绘示)吸入。人体因各种原因,(比如疾病、饮食、所处环境或生活习惯)引生的恶性自由基,亦称有害自由基,可以与吸入的氢气还原成部份的水,而排出体外。间接减少人体自由基的数量,达到酸性体质还原至健康的碱性体质,可以抗氧化进而也达到消除慢性疾病效果。另外,液态药液经过雾化后形成1~5微米的药水粒子,经由吸入的方式,而透过鼻粘膜或肺泡直接吸收,可以更有利于人体吸收,也就是说较少雾化药液剂量即可达到原先一般口服或注射所需要药剂量的治疗效果,也因为使用少量雾化药液剂量,也间接降低药剂对人体产生的副作用。当然药液也可以是口服药溶于水后的混合液。因此,本发明通过具有氢氧与雾化药液的吸入式药物组合物,供人体吸入后可以达到更好的治疗或医疗效果。
相比于现有技术,本发明提供一种用于治疗心脏病的吸入式药物组合物及其制备方法,本发明吸入式药物组合物除了可以通过氢气以去除患者体内的恶性自由基,并通过雾化药液以增加患者的药物吸收疗效,通过较少雾化药液剂量即可达到原先一般口服或注射所需要药剂量的治疗效果,因而能使用少量雾化药液剂量,间接地降低药剂对人体产生的副作用。
通过以上较佳具体实施例的详述,希望能更加清楚描述本发明的特征与精神,而并非以上述所揭露的较佳具体实施例来对本发明的范畴加以限制。相反地,其目的是希望能涵盖各种改变及具相等性的安排于本发明所欲申请的专利范围的范畴内。因此,本发明所申请的专利范围的范畴应根据上述的说明作最宽广的解释,以致使其涵盖所有可能的改变以及具相等性的安排。
Claims (20)
1.一种用于治疗心脏病的吸入式药物组合物,包含第一气体及雾化药液,其中该第一气体包含氢气,氢气占该吸入式药物组合物的气体体积浓度在2%~96%之间,该雾化药液包含选自乙酰水杨酸(Acetylsalicylic Acid)、氯吡格雷(Clopidogrel)、普萘洛尔(Propranolol)、阿替洛尔(Atenolol)、纳多洛尔(Nadolol)、卡维地洛(Carvedilol)、硝苯吡啶(Nifedipine)、地尔硫卓(Diltiazem)、维拉帕米(Verapamil)、硝酸异山梨酯(Isosorbide Dinitrate)、尼可地尔(Nicorandil)以及硝酸甘油(Nitroglycerin)所组成的组中之一或其组合。
2.如权利要求1所述的用于治疗心脏病的吸入式药物组合物,其特征在于,该第一气体还包含氧气。
3.如权利要求2所述的用于治疗心脏病的吸入式药物组合物,其特征在于,该第一气体是由电解水所产生的氢氧混合气体,其中氢气与氧气的体积比为2:1。
4.如权利要求2所述的用于治疗心脏病的吸入式药物组合物,其特征在于,还包含第二气体,用于降低该吸入式药物组合物中氢气的气体体积浓度,该第二气体选自由空气、水蒸汽、惰性气体、氧气及其组合所组成的组中的一种气体。
5.如权利要求1所述的用于治疗心脏病的吸入式药物组合物,其特征在于,氢气占该吸入式药物组合物的气体体积浓度在2%~66.66%之间。
6.如权利要求1所述的用于治疗心脏病的吸入式药物组合物,其特征在于,氢气占该吸入式药物组合物的气体体积浓度在4.7%~66.66%之间。
7.如权利要求1所述的用于治疗心脏病的吸入式药物组合物,其特征在于,氢气占该吸入式药物组合物的气体体积浓度在60%~66.66%之间。
8.如权利要求1所述的用于治疗心脏病的吸入式药物组合物,其特征在于,氢气占该吸入式药物组合物的气体体积浓度大于66.66%。
9.如权利要求1所述的用于治疗心脏病的吸入式药物组合物,其特征在于,该雾化药液是由针对一药液进行雾化或挥发所产生。
10.如权利要求9所述的用于治疗心脏病的吸入式药物组合物,其特征在于,该药液包含选自乙酰水杨酸(Acetylsalicylic Acid)、氯吡格雷(Clopidogrel)、普萘洛尔(Propranolol)、阿替洛尔(Atenolol)、纳多洛尔(Nadolol)、卡维地洛(Carvedilol)、硝苯吡啶(Nifedipine)、地尔硫卓(Diltiazem)、维拉帕米(Verapamil)、硝酸异山梨酯(Isosorbide Dinitrate)、尼可地尔(Nicorandil)以及硝酸甘油(Nitroglycerin)所组成的组中之一或其组合。
11.一种用于治疗心脏病的吸入式药物组合物的制备方法,包含下列步骤:
(S1)制备第一气体,该第一气体包含氢气;
(S2)雾化一药液以产生雾化药液,该药液包含选自乙酰水杨酸(Acetylsalicylic Acid)、氯吡格雷(Clopidogrel)、普萘洛尔(Propranolol)、阿替洛尔(Atenolol)、纳多洛尔(Nadolol)、卡维地洛(Carvedilol)、硝苯吡啶(Nifedipine)、地尔硫卓(Diltiazem)、维拉帕米(Verapamil)、硝酸异山梨酯(Isosorbide Dinitrate)、尼可地尔(Nicorandil)以及硝酸甘油(Nitroglycerin)所组成的组中之一或其组合;以及
(S3)混合该第一气体以及该雾化药液以产生该吸入式药物组合物,其中氢气占该吸入式药物组合物的气体体积浓度在2%~96%之间。
12.如权利要求11所述的用于治疗心脏病的吸入式药物组合物的制备方法,其特征在于,于步骤(S2)之后另包含下列步骤:
(S23)准备第二气体。
13.如权利要求12所述的用于治疗心脏病的吸入式药物组合物的制备方法,其特征在于,该步骤(S3)为混合该第一气体、该第二气体以及该雾化药液以产生该吸入式药物组合物。
14.如权利要求11所述的用于治疗心脏病的吸入式药物组合物的制备方法,其特征在于,步骤(S1)为电解水以产生该第一气体,该第一气体含氢氧混合气体,其中氢气与氧气的体积比为2:1。
15.如权利要求12所述的用于治疗心脏病的吸入式药物组合物的制备方法,其特征在于,该第二气体用于降低该吸入式药物组合物中氢气的气体体积浓度。
16.如权利要求12所述的用于治疗心脏病的吸入式药物组合物的制备方法,其特征在于,该第二气体为选自由空气、水蒸汽、惰性气体、氧气及其组合所组成的组中的一种气体。
17.如权利要求11所述的用于治疗心脏病的吸入式药物组合物的制备方法,其特征在于,氢气占该吸入式药物组合物的气体体积浓度在2%~66.66%之间。
18.如权利要求11所述的用于治疗心脏病的吸入式药物组合物的制备方法,其特征在于,氢气占该吸入式药物组合物的气体体积浓度在4.7%~66.66%之间。
19.如权利要求11所述的用于治疗心脏病的吸入式药物组合物的制备方法,其特征在于,氢气占该吸入式药物组合物的气体体积浓度在60%~66.66%之间。
20.如权利要求11所述的用于治疗心脏病的吸入式药物组合物的制备方法,其特征在于,氢气占该吸入式药物组合物的气体体积浓度大于66.66%。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW103110985A TWI590837B (zh) | 2014-03-25 | 2014-03-25 | 一種用於治療心臟病之吸入式醫藥組成物及其備製方法 |
TW103110985 | 2014-03-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104940223A true CN104940223A (zh) | 2015-09-30 |
Family
ID=54067009
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410337827.1A Pending CN104940223A (zh) | 2014-03-25 | 2014-07-16 | 一种用于治疗心脏病的吸入式药物组合物及其制备方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US9375396B2 (zh) |
JP (1) | JP2015183006A (zh) |
KR (1) | KR20150111328A (zh) |
CN (1) | CN104940223A (zh) |
DE (1) | DE102015104360A1 (zh) |
TW (1) | TWI590837B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113599387A (zh) * | 2021-09-15 | 2021-11-05 | 山东中医药大学附属医院 | 一种复方制剂及其在制备治疗心绞痛药物中的用途 |
WO2024078544A1 (zh) * | 2022-10-11 | 2024-04-18 | 上海氢医医疗科技有限公司 | 氢气吸入干预早产儿促进发育 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI586383B (zh) * | 2014-04-18 | 2017-06-11 | 林信湧 | 一種用於治療關節炎之吸入式醫藥組成物及其備製方法 |
JP6666701B2 (ja) * | 2015-12-01 | 2020-03-18 | 日本光電工業株式会社 | 水素ガス供給装置 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1228706A (zh) * | 1996-08-27 | 1999-09-15 | 梅塞尔·格里斯海姆有限公司 | 含氢的药物产品 |
US20100030091A1 (en) * | 2008-07-24 | 2010-02-04 | Fine David H | Methods for diagnosing and treating a heart condition in a patient |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19734279A1 (de) * | 1997-08-07 | 1999-02-11 | Messer Griesheim Gmbh | Wasserstoffhaltiges Medikament |
EP1421952A4 (en) * | 2001-08-22 | 2005-02-16 | Mitsuhiro Yokota | MYOKARDZELL-APOPTOSIS INHIBITORS |
US20080066739A1 (en) * | 2006-09-20 | 2008-03-20 | Lemahieu Edward | Methods and systems of delivering medication via inhalation |
EP3552603A1 (en) * | 2009-03-18 | 2019-10-16 | Incarda Therapeutics, Inc. | Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration |
GB0921481D0 (en) | 2009-12-08 | 2010-01-20 | Vectura Ltd | Process and product |
KR101511008B1 (ko) * | 2012-06-04 | 2015-04-10 | 미즈 가부시키가이샤 | 생체용 고농도 수소 가스 공급 장치 |
-
2014
- 2014-03-25 TW TW103110985A patent/TWI590837B/zh active
- 2014-07-16 CN CN201410337827.1A patent/CN104940223A/zh active Pending
-
2015
- 2015-03-20 US US14/664,491 patent/US9375396B2/en active Active
- 2015-03-24 DE DE102015104360.2A patent/DE102015104360A1/de not_active Withdrawn
- 2015-03-24 JP JP2015060834A patent/JP2015183006A/ja active Pending
- 2015-03-25 KR KR1020150041704A patent/KR20150111328A/ko not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1228706A (zh) * | 1996-08-27 | 1999-09-15 | 梅塞尔·格里斯海姆有限公司 | 含氢的药物产品 |
US20100030091A1 (en) * | 2008-07-24 | 2010-02-04 | Fine David H | Methods for diagnosing and treating a heart condition in a patient |
Non-Patent Citations (3)
Title |
---|
AVINASH M.CONTRACTOR,ET AL: "Development and Evaluation of an Inhalation Aerosol of Nitroglycerin", 《JOURNAL OF PHARMACEUTICAL SCIENCES》 * |
K.HAYASHIDA,ET AL: "Inhalation of hydrogen gas reduces infarct size in the rat model of myocardial ischemia–reperfusion injury", 《BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS》 * |
杨俊芹等: "氧气雾化吸入硝酸甘油对急性心肌梗死后血清cTnI的影响", 《实用医技杂志》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113599387A (zh) * | 2021-09-15 | 2021-11-05 | 山东中医药大学附属医院 | 一种复方制剂及其在制备治疗心绞痛药物中的用途 |
WO2024078544A1 (zh) * | 2022-10-11 | 2024-04-18 | 上海氢医医疗科技有限公司 | 氢气吸入干预早产儿促进发育 |
Also Published As
Publication number | Publication date |
---|---|
US20150272868A1 (en) | 2015-10-01 |
JP2015183006A (ja) | 2015-10-22 |
TWI590837B (zh) | 2017-07-11 |
US9375396B2 (en) | 2016-06-28 |
TW201536359A (zh) | 2015-10-01 |
KR20150111328A (ko) | 2015-10-05 |
DE102015104360A1 (de) | 2015-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN203291353U (zh) | 保健气体产生器 | |
CN104940209A (zh) | 一种用于治疗阿兹海默症的吸入式药物组合物及其制备方法 | |
TWI601542B (zh) | 一種用於治療肺癌之吸入式醫藥組成物及其備製方法 | |
CN103800979A (zh) | 保健气体产生器 | |
CN103785091A (zh) | 保健气体产生系统 | |
CN104940223A (zh) | 一种用于治疗心脏病的吸入式药物组合物及其制备方法 | |
CN105012336A (zh) | 一种用于治疗痛风的吸入式药物组合物及其制备方法 | |
CN104940224A (zh) | 一种用于治疗帕金森氏症的吸入式药物组合物及其制备方法 | |
TWI594772B (zh) | 一種用於治療高血壓之吸入式醫藥組成物及其備製方法 | |
CN105012337A (zh) | 一种用于治疗关节炎的吸入式药物组合物及其制备方法 | |
TWI590838B (zh) | 一種用於治療糖尿病之吸入式醫藥組成物及其備製方法 | |
CN105012277A (zh) | 一种用于治疗肾脏病的吸入式药物组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150930 |